中
繁
EN
Search form
Search this site
For Patients
Investors
Careers
Contact
Home
About Us
Our Story
Leadership
Board of Directors
Platform & Pipeline
Platform
Pipeline
Publications
Partnership
News
Company News
Media Report
45
press releases in total
Year
-Year
2023
2022
2021
2020
2019
2018
2023
Dec 7, 2023
Jacobio Pharma to Present Data of KRAS G12C Inhibitor Glecirasib in Patients with Pancreatic Cancer and Other Solid Tumors at the 2024 ASCO GI
[More]
Oct 27, 2023
Jacobio Completes First Patient Dosage of Glecirasib in a Pivotal Clinical Trial for the Treatment of Pancreatic Cancer in China
[More]
Oct 22, 2023
Jacobio Pharma Presents Clinical Results of Glecirasib in Combination with JAB-3312 at ESMO
[More]
Aug 30, 2023
Jacobio Pharma Announces 2023 Interim Results
[More]
Aug 7, 2023
Jacobio Pharma Announces Breakthrough Therapy Designation from China CDE for KRAS G12C Inhibitor Glecirasib for the Treatment of Pancreatic Cancer
[More]
Jul 21, 2023
Jacobio Pharma to Present Data of Glecirasib in Combination with JAB-3312 at the 2023 ESMO Conference
[More]
Jul 4, 2023
Jacobio Receives CDE Approval for Glecirasib’s Pancreatic Cancer Pivotal Study in China
[More]
Jun 29, 2023
Jacobio Pharma Presents Clinical Results of Glecirasib in Colorectal Cancer
[More]
Jun 8, 2023
Jacobio Pharma Receives IND Approval for PARP7 Inhibitor JAB-26766 in China
[More]
Apr 18, 2023
Jacobio Pharma Presented Data of Three Preclinical Studies at the 2023 AACR Annual Meeting
[More]
Apr 4, 2023
Jacobio Pharma Receives IND Approval for LIF mAb JAB-BX300 in China
[More]
Mar 22, 2023
Jacobio announces clinical collaboration to evaluate CD73 monoclonal antibody JAB-BX102 in combination with KEYTRUDA® (pembrolizumab) for patients with cancer
[More]
Mar 22, 2023
Jacobio Pharma Announces 2022 Annual Results
[More]
Mar 17, 2023
Jacobio Receives IND Approval for GUE Inhibitor JAB-24114 in China
[More]
Mar 15, 2023
Jacobio Pharma to Present Data of Three Preclinical Studies at the 2023 AACR Annual Meeting
[More]
Jan 8, 2023
Jacobio Completes First Patient Dosage of Aurora A Inhibitor JAB-2485 in U.S.
[More]
2022
Dec 16, 2022
Jacobio’s KRAS G12C Inhibitor JAB-21822 was Granted Breakthrough Therapy Designations by China CDE
[More]
Dec 2, 2022
Jacobio’s Preclinical Results of KRAS G12C Inhibitor in Combination with SHP2 Inhibitor Will be Presented at the ESMO Asia Congress 2022
[More]
Oct 29, 2022
Jacobio Receives IND Approval for Aurora A Inhibitor JAB-2485 in China
[More]
Oct 13, 2022
Jacobio Pharma to Collaborate with Merck on Clinical Trial of JAB-21822 in Combination with Cetuximab
[More]
Pages
1
2
3
›
»
京公网安备 11030102011242号